Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Among authors: belmans a. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: belmans a. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Dubois CL, Belmans A, Granger CB, Armstrong PW, Wallentin L, Fioretti PM, López-Sendón JL, Verheugt FW, Meyer J, Van de Werf F; ASSENT-3 Investigators. Dubois CL, et al. Among authors: belmans a. J Am Coll Cardiol. 2003 Oct 1;42(7):1178-85. doi: 10.1016/s0735-1097(03)00917-3. J Am Coll Cardiol. 2003. PMID: 14522476 Free article. Clinical Trial.
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial.
Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzi M, Herbots L, Sinnaeve P, Dens J, Maertens J, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Bormans G, Nuyts J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F. Janssens S, et al. Among authors: belmans a. Lancet. 2006 Jan 14;367(9505):113-21. doi: 10.1016/S0140-6736(05)67861-0. Lancet. 2006. PMID: 16413875 Clinical Trial.
Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial.
Mertens P, Maes A, Nuyts J, Belmans A, Desmet W, Esplugas E, Charlier F, Figueras J, Sambuceti G, Schwaiger M, Mortelmans L, Van de Werf F; PSALM investigators. Mertens P, et al. Among authors: belmans a. Am Heart J. 2006 Jul;152(1):125.e1-8. doi: 10.1016/j.ahj.2006.04.020. Am Heart J. 2006. PMID: 16824841 Clinical Trial.
Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study.
Herbots L, D'hooge J, Eroglu E, Thijs D, Ganame J, Claus P, Dubois C, Theunissen K, Bogaert J, Dens J, Kalantzi M, Dymarkowski S, Bijnens B, Belmans A, Boogaerts M, Sutherland G, Van de Werf F, Rademakers F, Janssens S. Herbots L, et al. Among authors: belmans a. Eur Heart J. 2009 Mar;30(6):662-70. doi: 10.1093/eurheartj/ehn532. Epub 2008 Dec 23. Eur Heart J. 2009. PMID: 19106196 Clinical Trial.
A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study.
Buysschaert I, Carruthers KF, Dunbar DR, Peuteman G, Rietzschel E, Belmans A, Hedley A, De Meyer T, Budaj A, Van de Werf F, Lambrechts D, Fox KA. Buysschaert I, et al. Among authors: belmans a. Eur Heart J. 2010 May;31(9):1132-41. doi: 10.1093/eurheartj/ehq053. Epub 2010 Mar 15. Eur Heart J. 2010. PMID: 20231156 Free PMC article.
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction.
Dubois C, Liu X, Claus P, Marsboom G, Pokreisz P, Vandenwijngaert S, Dépelteau H, Streb W, Chaothawee L, Maes F, Gheysens O, Debyser Z, Gillijns H, Pellens M, Vandendriessche T, Chuah M, Collen D, Verbeken E, Belmans A, Van de Werf F, Bogaert J, Janssens S. Dubois C, et al. Among authors: belmans a. J Am Coll Cardiol. 2010 May 18;55(20):2232-43. doi: 10.1016/j.jacc.2009.10.081. J Am Coll Cardiol. 2010. PMID: 20466204 Free article.
81 results